UNCY
Unicycive TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
If OLC is approved on the current June 29, 2026 timeline, UNCY moves from a single-asset regulatory story toward a launch-stage nephrology commercial setup with management already describing pre-launch infrastructure, dialysis engagement, and a focused sales plan [#10-K-2026-03-30].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -14.0.
What can break
Commercial uptake is unproven even if approved, with reimbursement, dialysis contracting, and sales-force execution still ahead [#10-K-2026-03-30].
Momentum
3
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $15.00 · Bear $3.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $37.50
Why
Momentum3 · Δ7d -1.5
Value41 · Δ7d +0.1
Sentiment84 · Δ7d -14.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
3
26% active weight
Current posture
7d trendSoftening
Δ7d
-1.5
Δ21d
-33.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
84
34% active weight
Current posture
7d trendSoftening
Δ7d
-14.0
Δ21d
+36.2
Why this grade
Composite grade D. Momentum 3.1 / Value 41.1 / Sentiment 84.1
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$151.92M
Beta
1.85
Shares Out
26.7M
P/E (TTM) · Derived
-3.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.47
Rev YoY
-100.0%
EPS YoY
+6.9%
Gross Margin
+57.9%
Op Margin
-
Net Debt
-$41.07M
Current Ratio
2.40
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology